LOGIN  |  REGISTER
Viking Therapeutics
Viking Therapeutics

Owens & Minor to Present at the 2024 Baird Global Healthcare Conference

September 09, 2024 | Last Trade: US$2.69 0.09 3.46

RICHMOND, Va. / Sep 09, 2024 / Business Wire / Owens & Minor, Inc. (NYSE: OMI), announced today that Ed Pesicka, the Company’s President and Chief Executive Officer and Jon Leon, Corporate Treasurer and interim Chief Financial Officer, will participate in a fireside chat at 1:25 p.m. Eastern Daylight Time on Tuesday, September 10, 2024 at Baird’s Global Healthcare Conference in New York City. Owens & Minor is also hosting one-on-one meetings with investors at the conference.

About Owens & Minor

Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.

 

Assertio

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page